Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute. Dr. Fry, a world-renowned expert in chimeric antigen receptor T cell (CAR T) therapies, has devoted part of his time to the University of Colorado as a clinical professor of pediatric oncology since joining Sana. He continues to work in his current Sana role without change while serving as the Institute’s Executive Director.

“Terry is a leader in the cell and gene therapy space, particularly in developing CAR T therapies for cancer patients. We are proud of Terry and his appointment at the University of Colorado Gates Institute, as his close collaboration with academia will continue to be extremely valuable to the field and to Sana as we explore diverse scientific tools to modify genes and use cells as medicines to change the outcome of many human diseases,” said Steve Harr, Sana’s President and Chief Executive Officer. “Terry’s appointment further underscores the high caliber of talent that we have throughout the Sana organization and adds to the number of our team leading institutes in top academic centers.”

Dr. Fry added, “Bringing innovative therapies to patients remains my first priority, and I am optimistic about the pipeline we are progressing at Sana. My continued involvement in the academic arena fuels greater understanding into novel territories in gene and cell therapy with the goal of bridging and leveraging new insights across industry and academia to propel the field forward.”

Yesterday, the University of Colorado announced the creation of the Gates Institute, a state-of-the-art facility that will focus on rapidly translating laboratory findings into regenerative, cellular, and gene therapies for patients. Working in partnership with CU Anschutz, the Gates Institute, fueled by a philanthropic investment from the Gates Frontiers Fund, and an investment by CU Anschutz, is expected to grow to $200 million over the next five years. The institute will build on the success of the Gates Center for Regenerative Medicine and Gates Biomanufacturing Facility, which have conducted groundbreaking stem cell research for cancer and rare diseases, pioneering new therapies in recent years. Dr. Fry will become its Executive Director.

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision, progress, and business plans, the scope of Dr. Fry’s employment with Sana, and the potential value to the Company of Dr. Fry’s collaboration with academia. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 10, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
[email protected]
[email protected]